Logo image of RZLT

REZOLUTE INC (RZLT) Stock Fundamental Analysis

USA - NASDAQ:RZLT - US76200L3096 - Common Stock

8.86 USD
-0.15 (-1.66%)
Last: 10/21/2025, 8:00:02 PM
9 USD
+0.14 (+1.58%)
After Hours: 10/21/2025, 8:00:02 PM
Fundamental Rating

3

Overall RZLT gets a fundamental rating of 3 out of 10. We evaluated RZLT against 534 industry peers in the Biotechnology industry. While RZLT has a great health rating, there are worries on its profitability. RZLT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RZLT had negative earnings in the past year.
In the past year RZLT has reported a negative cash flow from operations.
RZLT had negative earnings in each of the past 5 years.
In the past 5 years RZLT always reported negative operating cash flow.
RZLT Yearly Net Income VS EBIT VS OCF VS FCFRZLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -42.40%, RZLT perfoms like the industry average, outperforming 56.37% of the companies in the same industry.
RZLT's Return On Equity of -45.90% is fine compared to the rest of the industry. RZLT outperforms 68.35% of its industry peers.
Industry RankSector Rank
ROA -42.4%
ROE -45.9%
ROIC N/A
ROA(3y)-45.28%
ROA(5y)-42.37%
ROE(3y)-49.01%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
RZLT Yearly ROA, ROE, ROICRZLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K 4K 6K

1.3 Margins

RZLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RZLT Yearly Profit, Operating, Gross MarginsRZLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

8

2. Health

2.1 Basic Checks

RZLT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RZLT has been increased compared to 5 years ago.
There is no outstanding debt for RZLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RZLT Yearly Shares OutstandingRZLT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
RZLT Yearly Total Debt VS Total AssetsRZLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

An Altman-Z score of 33.11 indicates that RZLT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 33.11, RZLT belongs to the top of the industry, outperforming 94.19% of the companies in the same industry.
There is no outstanding debt for RZLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 33.11
ROIC/WACCN/A
WACCN/A
RZLT Yearly LT Debt VS Equity VS FCFRZLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 14.37 indicates that RZLT has no problem at all paying its short term obligations.
RZLT's Current ratio of 14.37 is amongst the best of the industry. RZLT outperforms 89.14% of its industry peers.
A Quick Ratio of 14.37 indicates that RZLT has no problem at all paying its short term obligations.
RZLT's Quick ratio of 14.37 is amongst the best of the industry. RZLT outperforms 89.33% of its industry peers.
Industry RankSector Rank
Current Ratio 14.37
Quick Ratio 14.37
RZLT Yearly Current Assets VS Current LiabilitesRZLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

RZLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.07%, which is quite impressive.
EPS 1Y (TTM)27.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 28.09% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.84%
EPS Next 2Y4.39%
EPS Next 3Y20.6%
EPS Next 5Y28.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RZLT Yearly Revenue VS EstimatesRZLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M
RZLT Yearly EPS VS EstimatesRZLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RZLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RZLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RZLT Price Earnings VS Forward Price EarningsRZLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RZLT Per share dataRZLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as RZLT's earnings are expected to grow with 20.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.39%
EPS Next 3Y20.6%

More info and screens

0

5. Dividend

5.1 Amount

RZLT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REZOLUTE INC

NASDAQ:RZLT (10/21/2025, 8:00:02 PM)

After market: 9 +0.14 (+1.58%)

8.86

-0.15 (-1.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-17 2025-09-17/amc
Earnings (Next)11-05 2025-11-05
Inst Owners86.69%
Inst Owner Change-0.02%
Ins Owners1.38%
Ins Owner Change0.13%
Market Cap804.75M
Analysts86.25
Price Target14.28 (61.17%)
Short Float %9.8%
Short Ratio7.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.08%
Min EPS beat(2)-18.3%
Max EPS beat(2)-15.86%
EPS beat(4)2
Avg EPS beat(4)3.16%
Min EPS beat(4)-18.3%
Max EPS beat(4)34.64%
EPS beat(8)4
Avg EPS beat(8)-1.73%
EPS beat(12)8
Avg EPS beat(12)7.48%
EPS beat(16)10
Avg EPS beat(16)7.22%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5%
PT rev (3m)6.78%
EPS NQ rev (1m)-19.1%
EPS NQ rev (3m)-26.19%
EPS NY rev (1m)-7.86%
EPS NY rev (3m)-7.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.96
P/tB 4.96
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0
BVpS1.78
TBVpS1.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.4%
ROE -45.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.28%
ROA(5y)-42.37%
ROE(3y)-49.01%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.37
Quick Ratio 14.37
Altman-Z 33.11
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.91%
EPS Next Y-6.84%
EPS Next 2Y4.39%
EPS Next 3Y20.6%
EPS Next 5Y28.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.41%
OCF growth 3YN/A
OCF growth 5YN/A